Emmanuel Martinod

Prof. Emmanuel Martinod

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2018 in JAMA
Verified
Journal Article
Open access
PDF file
EMEmmanuel Martinod
Emmanuel Martinod
KCKader Chouahnia
Kader Chouahnia
DRDana M. Radu
Dana M. Radu
PJPascal Joudiou
Pascal Joudiou
YUYurdagul Uzunhan
Yurdagul Uzunhan
EVEric Vicaut
Eric Vicaut
Quiz Ref ID Over the last decade, new procedures in the field of airway transplantation have gained attention primarily through case reports or small studies.1-6 Due to the lack of prospective data, these interventions have failed to achieve standard of care status. An efficient airway replacement could potentially benefit many patients with lung cancer and eliminate the need for high-risk thoracic surgical procedures including pneumonectomies. Airway replacement also could be an option for patients with end-stage tracheobronchial disease for whom palliative treatment is often proposed.

1 May 2017 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
EMEmmanuel Martinod
Emmanuel Martinod
JPJoseph Paquet
Joseph Paquet
HDHervé Dutau
Hervé Dutau
DRDana M. Radu
Dana M. Radu
MBMorad Bensidhoum
Morad Bensidhoum
HPHervé Petite
Hervé Petite

2 July 2022 in American Journal of Transplantation
Verified
Journal Article
Open access
EMEmmanuel Martinod
Emmanuel Martinod
DRDana M. Radu
Dana M. Radu
IOilaria onorati
ilaria onorati
APAna Maria Santos Portela
Ana Maria Santos Portela
MPMarine Peretti
Marine Peretti
EVEric Vicaut
Eric Vicaut
Over the past 25 years, we have demonstrated the feasibility of airway bioengineering using stented aortic matrices experimentally then in a first-in-human trial (n = 13). The present TRITON-01 study analyzed all the patients who had airway replacement at our center to confirm that this innovative approach can be now used as usual care. For each patient, the following data were prospectively collected: postoperative mortality and morbidity, late airway complications, stent removal and status at last follow-up on November 2, 2021. From October 2009 to October 2021, 35 patients had airway replacement for malignant (n = 29) or benign (n = 6) lesions. The 30-day postoperative mortality and morbidity rates were 2.9% (n = 1/35) and 22.9% (n = 8/35) respectively. At a median follow-up of 29.5 months (range 1-133 months), 27 patients were alive. There have been no deaths directly related to the implanted bioprosthesis. Eighteen patients (52.9%) had stent-related granulomas requiring a bronchoscopic treatment. Ten among 35 patients (28.6%) achieved a stent free survival. The actuarial 2- and 5-year survival rates (Kaplan-Meier estimates) were respectively 88% and 75%. The TRITON-01 study confirmed that airway replacement using stented aortic matrices can be proposed as usual care at our center. Clinicaltrials.gov Identifier: NCT04263129.

1 October 2002 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
EMEmmanuel Martinod
Emmanuel Martinod
JAJacques F Azorin
Jacques F Azorin
DSDanielle Sadoun
Danielle Sadoun
MDMarie-Dominique Destable
Marie-Dominique Destable
PTPhilippe Le Toumelin
Philippe Le Toumelin
DVDominique Valeyre
Dominique Valeyre

24 July 2020 in Thorax
Verified
Journal Article
Closed access
PDF file
EMEmmanuel Martinod
Emmanuel Martinod
APAna-Maria Portela
Ana-Maria Portela
YUYurdagül Uzunhan
Yurdagül Uzunhan
OFOlivia Freynet
Olivia Freynet
STSalam Abou Taam
Salam Abou Taam
GLGuillaume Lebreton
Guillaume Lebreton
The use of extracorporeal membrane oxygenation for high-risk rigid bronchoscopy has been reported in few urgent cases. We report our experience with this approach which was planned electively in five cases on 202 procedures (2.5%). It was proposed because of the potential inability to ventilate the lungs using conventional techniques due to extensive tracheobronchial lesions or the risk of major intraoperative bleeding related to disease characteristics. There were no intraoperative complications and postoperative course was favourable in all patients. With a maximum follow-up of 3 years and 7 months, all patients are alive with no tracheostomy despite major morbidities.

24 June 2023 in JTCVS Techniques
Verified
Journal Article
Open access
IOIlaria Onorati
Ilaria Onorati
DRDana M. Radu
Dana M. Radu
APAna Maria Santos Portela
Ana Maria Santos Portela
MPMarine Peretti
Marine Peretti
PGPatrice Guiraudet
Patrice Guiraudet
EMEmmanuel Martinod
Emmanuel Martinod
Recent studies have demonstrated the feasibility and favorable long-term results of tracheobronchial replacement using stented cryopreserved aortic allografts. We propose to investigate the outcomes of this emerging technique in the subgroup of patients with extensive tracheal cancer. This study was based on 13 patients with primary extensive tracheal cancer extracted from the prospective registry TRITON-01 (ClinicalTrials.gov Identifier: NCT04263129), which included 40 patients in total. We analyzed early and late outcomes in this subset of patients. From March 2019 to September 2022, 13 patients were included in the study. There were 9 female and 4 male patients, with a mean age of 53.9 years [36-71 years]. They had tracheal replacement for extended adenoid cystic carcinoma (n = 11), squamous cell carcinoma (n = 1), and mucoepidermoid carcinoma (n = 1). A venovenous extracorporeal membrane oxygenation was used in the 6 last cases. The mean length of resection was 81 mm [50-120 mm]. There was no 30-day postoperative mortality. A complete resection (R0) was achieved in 11 patients. The main late complications consisted of tracheal granulomas related to the stent and requiring repeated bronchoscopies (n = 9), pneumonia (n = 3), airway infection (n = 1), bronchoesophageal fistula (n = 1), mechanical stent obstruction requiring change (n = 2), and mediastinitis treated by antibiotics, drainage, and omentoplasty (n = 1). With a maximal follow-up of 3 years and 7 months, cancer recurrence was observed in 2 patients. All patients were alive at last follow-up except 2 (84.6%). Airway replacement using stented CAA represents a feasible and promising solution for extensive tracheal cancer.